Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Markets & Finance

Prudential Cuts Tanox to Underweight

From Standard & Poor's Equity Research

Tanox (TNOX) shares fell after Prudential downgraded the stock to underweight from neutral.

Analyst Ron Ellis says the downgrade is based on valuation, higher expenses, and difficulty in identifying a commercial partner in HIV for the company's TNX-355 drug. Ellis says he's increasing his operating expense estimate, as at least two more trials will have to be done for TNX-355 approval and a sales and marketing infrastructure will need to be built.

As such, Ellis does not assume profitability until 2009, which is in line with guidance, but a year behind his previous estimate and the current consensus forecast. Along with the downgrade, he cuts his $16 price target to $15. He maintains 24 cents 2006 loss and 4 cents 2007 loss estimates.

blog comments powered by Disqus